To address this, we used serum pharmacochemistry to identify and screen major absorbed components of HT, such as Salvianolic acid A, Isoxanthohumol, 4-Methoxycinnamic acid, and Pratol, and constructed a component-target-pathway network based on the major absorbed components using network pharmacology analysis, and several key targets of RA have also been confirmed by molecular docking that exhibiting strong binding affinity with components of HT, like TNF and MMP-9, the inflammation and bone destruction biomarkers. The gene discussed is MMP9; the disease is rheumatoid arthritis.